Dr. Paul Sieber continues his conversation with Dr. Todd Cohen around managing the advanced prostate cancer patient. The use of somatic and germline testing to support decision making within the treatment algorithm are discussed. Medical management changes of positive mutation carriers and the commercial use of PARP inhibitors are also explored.